#YoMeCorono is an initiative that channels solidarity with research on COVID-19. Thanks to your contributions, we develop new vaccines, investigate treatments and detection tests, study persistent COVID and face the future challenges posed by the virus.
OUR TEAM
We present to you part of our research staff and their work areas. Meet the real protagonists.
OUR INVESTIGATION
August: protection against the virus in people over 65 years of age
A study by IrsiCaixa shows that the levels of neutralizing antibodies in people over 65 years of age who live in residences and who have been vaccinated are much higher in those people who have also had the SARS-CoV-2 infection, compared to the that they have not passed it.
Find out more
July: extrapolate results in the different variants of the virus
IrsiCaixa confirms, by expanding previous studies, that Cetylpyridinium Chloride (CPC), a chemical component present in some mouthwashes, reduces more than 1.000 times the infectivity of the Alpha variant of SARS-CoV-2 - described for the first time in the United Kingdom. Joined - in studies carried out on cells in the laboratory.
Find out more
June: solutions against the Delta variant of SARS-CoV-2
IrsiCaixa isolates the Delta variant of SARS-CoV-3 - described for the first time in India - in the level 2 biosafety laboratories of the Center for Comparative Medicine and Bioimaging (CMCiB) in order to study it. The virus is obtained from a nasal swab sample from COVID-19 patients.
Find out more
Mayo: cellular immunity against the virus
About 8% of people who pass COVID-19 do not generate antibodies even after being infected with SARS-CoV-2. To understand how these people fight the virus, IrsiCaixa has compared the immune response of people who overcome COVID-19 with antibodies compared to those who do not generate them.
Find out more
April: COVID-19 in pregnant women
Thanks to funding from #YoMeCorono, IrsiCaixa begins a study to understand how SARS-CoV-2 behaves in pregnant women who were positive for COVID-19 at the time of giving birth. For this, samples of different tissues of the volunteers were collected and the presence of virus was evaluated.
Find out more
March: immunity against SARS-CoV-2, in detail
After the holding of a first pilot test in the Sala Apolo in Barcelona, in which the effectiveness of the screening and control measures with antigen tests was verified to avoid the transmission of the virus in closed environments with a large influx of people, it is held one second
Find out more
February: evaluation of new treatments and virus monitoring
Producing antibodies in the laboratory is a potential tool to provide immediate immunity to COVID-19 patients but also to those people whose vaccine has not had the desired effect. IrsiCaixa is carrying out a project, led by Julià Blanco, to develop these synthetic antibodies in the laboratory.
Find out more
January: efforts to study what we are facing, the new variants
The virus mutates to acquire evolutionary advantages that can compromise scientific advances in the field of COVID-19. That is why IrsiCaixa increases sequencing efforts, a tool that will allow better control of the epidemic, monitor variants and detect the appearance of new mutations.
Find out more
December: duration of protective immunity
To understand the evolution of the pandemic and assess the possibility of revaccination, it is essential to study how long immunity against SARS-CoV-2 lasts. IrsiCaixa shows that the levels of neutralizing antibodies, that is, with a protective effect against the virus, are maintained throughout the six months that the study lasted.
Find out more
November: we work with viruses from patients in the laboratory
IrsiCaixa begins to work in the facilities of the Center for Comparative Medicine and Bioimaging (CMCiB) with SARS-CoV-2 viruses obtained directly from patients, an alternative that replaces the artificial viruses widely used in the laboratory. This logistical advance allows for much more realistic studies similar to the infection process.
Find out more
October: looking for weak spots in SARS-CoV-2
A project is started to determine which cellular proteins are essential to allow or block the replication of SARS-CoV-2 and to evaluate possible drugs that target these proteins. In collaboration with the Pompeu Fabra University (UPF), the aim is to identify the essential host factors for the SARS-CoV-2 infection cycle.
Find out more
September: protection against the virus and new treatments
To determine to which parts of SARS-CoV-2 the neutralizing antibodies are directed –small arrows essential to block the virus–, IrsiCaixa has started studies to be able to isolate and characterize them. To do this, cells from people who have passed COVID-19 and have generated many neutralizing antibodies, specifically B lymphocytes, are used.
Find out more
August: new laboratory and new lines of research
Start-up of the new laboratory of the Center for Comparative Medicine and Bioimaging (CMCiB) of the Germans Trias i Pujol Research Institute (IGTP). The CMCiB adapts its level 3 biosafety laboratory in order to offer the strict biosafety conditions essential to work with SARS-CoV-2 from patients.
Find out more
July: antibodies developed in the laboratory
The evaluation of animal models that allow studying the effectiveness of bispecific neutralizing antibodies begins. These molecules, designed in IrsiCaixa, can block SARS-CoV-2 since they contain regions capable of recognizing two very specific parts of the virus and joining them, preventing entry into the host cell.
Find out more
June: production of artificial viruses similar to SARS-CoV-2
In June, IrsiCaixa began to efficiently produce SARS-CoV-2 pseudoviruses, which will make it possible to study the ability of neutralizing antibodies to block the virus and the possible effectiveness of new drugs. These pseudoviruses are man-made viruses that contain proteins characteristic of SARS-CoV-2 but cannot infect people.
Find out more
May: first vaccine and antibody designs
Trials of the first designs of the vaccine against SARS-CoV-2 are started in animal models, specifically, in mice. In parallel, IrsiCaixa designs bispecific antibodies, that is, they are directed at two different regions of the virus. These antibodies may have a therapeutic or preventive role for COVID-19.
Find out more
March-April: getting to know the virus
During the first months of the pandemic, the scientific community dedicates great efforts to studying this new virus, SARS-CoV-2. To provide solutions to the health emergency, IrsiCaixa isolates the virus to work with it and understand how it works. It also sequences the virus to find out its genome and what mutations may appear.
Find out more
WHY DONATE
Since the #YoMeCorono initiative was launched, More than 75.000 people and institutions from all corners of Europe have made their contribution in solidarity. Thanks to the fact that they "have been crowned", the research team led by Dr. Bonaventura Clotet has done scientific advances in a few months that under normal circumstances would have taken years. The virulence of this pandemic it requires quick solutions that can only be found thanks to contributions like yours.
We help you solve some of the most frequent doubts about the coronavirus. If you cannot find the answers you are looking for, we recommend that you go to official sources of information:
Persistent COVID consists of the persistence of symptoms related to the coronavirus beyond three months after diagnosis. Various organs can be affected and these patients can suffer affectations in the respiratory system, neurological and / or cognitive alterations, digestive complications, alteration of taste and smell, weight loss, sensation of shortness of breath, muscle and joint pain, asthenia, etc. These affectations prevent them from leading a normal life and require medical attention.
According to the protocol, if they are not very serious cases or immunosuppressed people, the patient can be desisolated 10 days after the onset of symptoms, although some of them still persist. Control PCR tests are not performed after isolation because it has been seen that they can be positive even though they are no longer infective.
However, it is not yet known with certainty whether people can transmit the virus once cured, nor is the risk of reinfection well known. Some studies indicate that infected people can continue to shed the virus for more than a month, but there are still doubts about this.
In each country there is a number of attention for emergencies and health assistance. In Spain, health competencies are transferred to the autonomous governments. Most of the administrations have increased their telephone service teams and have hired new telephone operators in order to avoid the saturation of calls to the usual emergency number, 112.
Many autonomous communities have also enabled specific numbers to respond to requests for information on the new coronavirus. Health recalls that people who suspect they have coronavirus due to symptoms or having been in direct contact with an infected person should not go to the emergency room or their health center, but to isolate themselves at home and use these phone numbers to find out.
These are the COVID-19 help numbers, community by community:
If you have a fever, cough, and shortness of breath, seek medical attention. If you have any other mild symptoms compatible with COVID-19, you should stay home as a precaution and be attentive to your evolution.
Moreover, if you have been in contact with a person who has been diagnosed, even if they have no symptoms, you could be infected. Seek medical attention to see if you need to be tested.
No. The WHO has issued general recommendations on these types of events, but refers to a risk assessment by local authorities when managing bans.
What the WHO does do is recommend postponing or reduce mass concentrations in places where there is community transmission, that is, where several groups of people are infected and knowledge about the origin of the transmission is lost.
Although some evidence indicates that regular saline rinsing can speed recovery from the common cold, it has not been shown to prevent respiratory infections, including those caused by the coronavirus.
In Spain, use of mask It is mandatory on public roads, in outdoor spaces and in any closed space for public use or that is open to the public whenever it is not possible to maintain a distance interpersonal security of at least 2 meters. However, there are some exceptions:
People who have some type of respiratory difficulty that may be aggravated by the use of a mask.
People in whom the use of a mask is contraindicated for duly justified health reasons, or who, due to their disability or dependency, present behavioral alterations that make its use unviable.
Development of activities in which, due to their very nature, the use of the mask is incompatible, such as the intake of food and beverages.
Cause of force majeure or situation of need.
The most basic are the surgical masks. They prevent people who wear them from transmitting infectious agents. They are for single use only and therefore cannot be reused.
HR self-filtering masks They are the ones that offer the greatest protection against the coronavirus, because they not only prevent the people who carry them from transmitting the infection, but also protect them from contagion. There are three types, depending on the percentage of protection they offer against these particles: FFP1 (the least effective), FFP2 and FFP3 (the most effective). They are only reusable if they are marked with the letter R and, in addition, in most cases, they have an expiration date.
HR homemade masks They do not replace the previous ones, but they can have a hygienic and barrier function to help prevent the spread of respiratory droplets that we expel when we cough, sneeze or speak.
El face shield it is another option to reduce transmission at the community level and is intended as a barrier, especially against reflex acts such as touching the face. Its use is compatible with the use of respiratory protection masks.
Before putting on the mask, you have to:
Wash your hands with soap and water or a hydroalcoholic solution.
Place it so that it covers the mouth and nose well, without gaps between the face and the mask, just enough to breathe.
Once put:
You must not touch it.
If you touch it, wash your hands well.
When you take it off, you have to:
Do it from the back or from the tapes that hold it, without touching the part that may be contaminated.
Throw it in a closed bag, if it is for single use.
If it is a cloth mask, wash it at 60 ° C.
Before and after, wash your hands with soap and water or a hydroalcoholic solution.
SOCIAL DISTANCE
Keep at least 1,5 meters away with other people. The virus is spread by direct contact with secretions and by respiratory droplets, tiny droplets that are expelled from the nose or mouth of an infected person by coughing, sneezing, or talking. If you are too close, you can inhale them and become infected.
HYGIENE AND DISINFECTION
Wash your hands often: use hydroalcoholic gel, or wash with soap and water. It is not necessary to use disinfectant soaps, ordinary hand soap, whether solid or liquid, is enough. The important thing is the duration of the friction, it must be at least 40 - 60 seconds.
Adopt respiratory hygiene measures: In general, avoid touching your eyes, nose, and mouth. When coughing or sneezing, cover your mouth and nose with a bent elbow or a tissue; Throw away the tissue immediately and wash your hands with an alcohol-based hand sanitizer, or soap and water.
Disinfection of spaces and surfaces: the biggest sources of infection are the places we frequent the most. Pay special attention to the following “hot spots”, which you should disinfect regularly: knobs, handrails and railings; bathroom and kitchen faucets; light switches; electronic devices such as the remote control of the television, mobile or tablet; workspaces such as desk, computer and accessories.
In addition, you also need to take certain precautions when you get home. As soon as you enter, it is important to wash your hands well and leave your shoes in the hall, so that the floor does not become another element of contagion.
How long does the COVID-19 virus stay on surfaces?
Various studies have shown that the COVID-19 virus can survive up to 72 hours on plastic and stainless steel surfaces, while on cardboard it would survive around 24 hours. The study also suggests that it could survive that long on doorknobs, computer keyboards, mice, subway bars or mobile phones. The virus is unlikely to survive on clothing or sheets, although testing continues.
The most important thing to know about coronavirus contact with surfaces is that they can be easily cleaned with common household disinfectants that will kill the virus.
MASKS
Masks have two basic functions: to protect other people from contamination from our saliva and to protect the nose and mouth from contamination from other people's saliva. They should be considered as an additional protection measure, provided they are used correctly, but they do not replace the rest of prevention measures.
MEDICINES
So far, there is no specific medicine to cure the disease and few drugs have shown efficacy against SARS-CoV-2.
Examples of treatments that work:
- Remdesivir: initially developed as a treatment for ebola, this antiviral has proven its usefulness reducing recovery time of mild, moderate and severe patients. This is not the case with those who start receiving it when they already need mechanical ventilation (respirator).
- Dexamethasone: is a well-known drug within the group of corticosteroids and It is used as a very powerful anti-inflammatory to treat practically all respiratory inflammatory diseases, such as COPD or asthma. Its use is associated with greater survival in COVID-19 patients.
Examples of discarded treatments:
- HIV treatments: a Despite the fact that in China they treated the population with HIV drugs during the early phases of the pandemic, the RECOVERY clinical trial, which recruited more than 11.000 patients in the United Kingdom, concluded that this treatment does not provide clinical benefit in hospitalized patients with COVID-19.
- Pneumonia vaccines: it has been shown that do not protect against COVID-19. It is a very new and different virus for which the scientific community must create a new specific vaccine. However, keep in mind that it is always advisable to get vaccinated against respiratory diseases.
Examples of treatments under study:
The possible efficacy of many different drugs and compounds against COVID-19 is currently being studied. Many of them can be grouped into the following categories:
- Neutralizing antibodies
With this type of treatment, antibodies are injected into the body to speed up and strengthen its response, to stop the infection and prevent it from getting worse. They can be antibodies monoclonal (they fight only a part of the virus, generally protein S) or polyclonal (attack different parts of the virus).
Along these lines, there are studies on the convalescent plasma administration, from people who have already overcome COVID-19 and who have already developed neutralizing antibodies, to people who have recently been infected.
They are also studied hyperimmune immunoglobulin (Ig) therapies. In the trial with Grifols immunoglobulin led by doctors Clotet i Mitjà from the Foundation for Fighting AIDS and Infectious Diseases, the immunoglobulin will be administered with a drug made up of polyclonal antibodies from different donors who have had the disease, selected and concentrated to maximize its effectiveness and attack different parts of the virus. Its administration, by subcutaneous injection, would allow it to be used more easily in CAPs, in hospital emergencies or even in residences, to avoid hospitalizations.
These antibodies can also be produced in the laboratory so that they can be administered therapeutically. In this sense, the IrsiCaixa AIDS Research Institute, thanks to donations from #YoMeCorono, is working on the development of synthetic antibodies that can be used against COVID-19.
The companies Regeneron and Eli Lilly have also created monoclonal antibody therapies, both licensed for emergency use (used but still under study) in the U.S. Trials indicated that these companies' antibodies reduced viral load and prevented hospitalizations for the worsening of the infection, but studies with patients are giving mixed results.
A key in antibody therapy seems to be in which phase of the infection it is used, since not much effect has been observed in already seriously ill patients, but the sooner it is administered.
- Antivirals
Faced with the health emergency caused by the pandemic, doctors and scientists began to review what drugs already available on the market for other diseases could be useful to combat COVID-19. Among them, the CBIG consortium research team, made up of IrsiCaixa, the Animal Health Research Center (CReSA), the Barcelona Supercomputing Center (BSC), with the support of Grifols and #YoMeCorono, has evaluated the effectiveness of 72 drugs to prevent SARS-CoV-2 infection in laboratory cells. Along these lines, various antivirals were studied, such as remdesivir, hydroxychloroquine and Aplidine, the latter being the most effective in the laboratory.
Currently there are still studies with different pre-existing drugs, such as those evaluating the use of antiviral cocktails to attack different mechanisms of the virus. In its day, this strategy was the one that managed to stop the mortality of HIV-AIDS.
They are also analyzed drugs that act against the cytokine storm It occurs in the most severe cases of COVID-19, an overreaction of the immune system to the infection. Although the production of cytokines is a protective mechanism that occurs in any inflammation and that usually acts in a controlled way, there are times when production becomes excessive, both in quantity and quality: cells are destroyed infected, in this case by SARS-CoV-2, but there is also damage to healthy cells.
- Anti-inflammatories
It is another type of medicine that is used to treat hyperinflammation that COVID causes in some cases. Like dexamethasone, widely used. To give some examples of studies on this type of drug, Grifols is testing its alpha-1 antitrypsin; Oxford and Lilly, baricitinib, also in cocktail with remdesivir.
After the first wave, the use of these drugs in the early stages of infection is considered one of the factors to reduce admissions to ICUs and deaths.
- Anticoagulants
Anticoagulants are another of the families of drugs that are given to many COVID-19 patients to prevent and treat venous or arterial thrombosis, pulmonary embolism and stroke that can lead to infection. The possible efficacy of various anticoagulant medications is being studied, including a classic one such as aspirin.
VACCINES
The scientific community is devoted to the studies of vaccines against SARS-CoV-2. According to the World Health Organization, more than 169 candidate vaccines against COVID-19 are being developed, one of them is the one supported by #YoMeCorono. From the WHO list, 26 are in the human trials phase.
So far, only three have been authorized for use in the European Union: Pfizer-BioNTech, Moderna and Oxford-Astrazeneca.. The three vaccines differ, but all of them have proven their efficacy and safety:
Effectiveness
Operation
The Pfizer-BioNTech and Moderna vaccines use messenger RNA, the genetic material that our cells read to make proteins. The Oxford-Astrazeneca uses a chimpanzee adenovirus as a vehicle to reach cells.
Temperature regime
A key advantage of AstraZeneca is the favorable storage and transport temperatures they require: between 2 º C and 8 º C. Pfizer can be stored between -80 º C and -60 º C, while that of Moderna, between -25 º C and -15 º C.
Price
Although neither the pharmaceutical companies nor the European Union have wanted to confirm its price due to the confidential nature of the contracts, it is known that the Astrazeneca vaccine would be the most affordable. Belgian Budget Minister Eva de Bleecker published the price of each vaccine through her Twitter account during a debate in the country's federal Parliament. According to the tweet - which he later deleted - the Pfizer-BioNtech vaccine would cost 12 euros, Moderna's 14,6 euros and AstraZeneca's 1,78 euros.
The COVID-19 vaccine, in addition to being a scientific challenge, it is also a logistical challenge: mass production capacity, global distribution of vaccines, administration policies and establishment of priority groups, etc.
Everything indicates that many more vaccines will be needed to be able to vaccinate globally, cover all groups in society and all possible mutations of the virus.
The people who should be tested for the coronavirus, according to the Centers for Disease Control and Prevention (CDC) are:
People who have symptoms consistent with COVID-19 contamination.
People who have had close contact (within two meters for a total of 15 minutes or more) with a confirmed case of COVID-19.
Anyone who has been requested or directed by their Primary Care Physician or health center to perform the detection.
When a person has symptoms of coronavirus or has been in contact with a positive, they should immediately inform their Primary Care doctor. He will be the one to decide if a diagnostic test is necessary to detect the virus. If so, these will be carried out mainly in the health center. For, perform a PCR or serological test a prescription is needed, both in public health and in private health. Tests of this type are not done on demand in any public health center if it is not prescribed by a health professional.
Another possibility that is on the table is the conducting a rapid antigen test in a private clinic, and pay to receive the test result.
PCR: confirms the presence of the virus and is used to diagnose people with symptoms of infection. A healthcare professional removes a nasopharyngeal sample, which is analyzed in a specialized laboratory to detect the genetic material of the virus. Results may take 24-72 hours.
SEROLOGY: confirms the immune system's response against the virus. It is used to know if there are antibodies in the blood and if they are from an active or past infection. A healthcare professional draws a blood sample. Results are obtained in a few hours.
QUICK ANTIGENS TEST: detects the presence of virus proteins. It allows the identification of people who are infected by SARS-CoV-2 at the time of the test, especially in the first five days after the presentation of symptoms. Depending on the epidemiological situation, this type of test can also be used to detect asymptomatic patients and to carry out screening. A nasopharyngeal sample is extracted but the test does not require a laboratory: the results can be obtained in the same place where the sample is taken (as with a pregnancy test, for example). Results are obtained in about 15 minutes.
The Spanish Society of Neonatology, the World Health Organization and other scientific societies recommend maintaining breastfeeding from birth, as long as the clinical conditions of the baby and the mother allow it, always taking isolation measures ( hand hygiene and mask).
Some cases of intrauterine or perinatal infection have been reported, but it is very rare and does not seem to be related to malformations of the baby at birth. Some infection of the baby a few days after birth has also been described, with mild symptoms in most cases.
From what is currently known, pregnant women do not seem to have a greater susceptibility to being infected by coronavirus, nor to presenting serious complications. Even so, it is important to diagnose and treat them early.
So far, the data do not suggest an increased risk of abortion in pregnant women with COVID-19.
It is known to be can cause reinfections, but they are very rare. Worldwide, there have been 31 confirmed cases of SARS-CoV-2 reinfection, although that could be an underestimation of the reporting delays and resource pressure in the ongoing pandemic. Most of these SARS-CoV-2 reinfections have been milder than the first encounters with the virus, although some have been more severe, and two people have died as a result.
On the other hand, it is difficult to determine if what these people are experiencing is a reinfection or a reactivation of the pre-existing COVID-19 within the body.
La duration of immunity generated by the SARS-CoV-2 infection continues to be one of the great unknowns of the pandemic. According a recent study named SIREN, developed by researchers at Public Health England, most people infected with the new coronavirus make a full recovery and are immune for several months. The study concludes that the antibodies provide 83% protection against COVID-19 reinfections over a five-month period. From #YoMeCorono, the immune response of patients who passed COVID-19 in the first wave is being monitored. So far, the participants have maintained antibodies against SARS-CoV-2 for six months.
Anyway, for now, the message is clear: Even if a person has passed COVID-19, they cannot forget to follow all prevention measures, because they could acquire the virus again and transmit it.
It is transmitted mainly by the direct contact with secretions and for the respiratory drops, small droplets that are expelled from the nose or mouth of an infected person when coughing, sneezing or talking. That is why it is so important to wear a mask, cover your mouth and nose with a handkerchief or the inside of your arm, wash your hands regularly and maintain a safe distance of two meters. Airborne transmission over distances of more than two meters seems unlikely.
El incubation period - the time that elapses between exposure to the SARS-CoV-2 virus and the moment symptoms start - usually around five or six days, but it can vary between 2 and 14 days.
COVID-19 presents a flu-like clinical symptoms. The most common symptoms are fever dry cough feeling short of breath, general discomfort and the loss of smell and taste.
80% of the cases are mild, but it is estimated that 1 in 5 people ends up presenting a serious condition. Older people and those with previous medical conditions such as high blood pressure, heart or lung problems, diabetes, or cancer, are more likely to have complications.
El first positive case coronavirus was detected 31 January 2020 in La Gomera. It was a German tourist who tested positive after having been in contact with a Chinese citizen in Germany. A month later, on February 25, the first case in the peninsula in Barcelona. It was also imported: an Italian woman who had traveled to northern Italy a few days before.
The general director of the WHO, Tedros Adhanom Ghebreyesus declared the pandemic el March 11 2020 after an extraordinary meeting. He did so alarmed by the levels of spread and severity of the disease, as well as by what he considered "alarming levels of inaction."
The origin of COVID-19 is unclear, although it most likely has an animal origin. A study led by scientist Maciej F. Boni, concludes that the virus from a bat population in Yunnan, in southeastern China, most likely jumped directly to humans in November 2019
COVID-19 is the infectious disease caused by the SARS-CoV-2 virus, a new type of coronavirus that can affect people. Coronaviruses are a very large family of viruses that cause a wide variety of conditions, from the common cold to more serious illnesses.
Both the SARS-CoV-2 and COVID-19 viruses were unknown before the outbreak broke out in Wuhan, China, in December 2019. Currently, COVID-19 is a pandemic that affects many countries around the world.